- Home
- IZM vs CGTX Comparison
IZM vs CGTX Comparison
Compare IZM & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IZM
- CGTX
- Stock Information
- Founded
- IZM 2011
- CGTX 2007
- Country
- IZM China
- CGTX United States
- Employees
- IZM N/A
- CGTX N/A
- Industry
- IZM Consumer Electronics/Video Chains
- CGTX Biotechnology: Pharmaceutical Preparations
- Sector
- IZM Consumer Discretionary
- CGTX Health Care
- Exchange
- IZM Nasdaq
- CGTX Nasdaq
- Market Cap
- IZM 21.1M
- CGTX 20.5M
- IPO Year
- IZM 2023
- CGTX 2021
- Fundamental
- Price
- IZM $2.37
- CGTX $0.24
- Analyst Decision
- IZM
- CGTX Strong Buy
- Analyst Count
- IZM 0
- CGTX 5
- Target Price
- IZM N/A
- CGTX $5.63
- AVG Volume (30 Days)
- IZM 32.4K
- CGTX 1.1M
- Earning Date
- IZM 07-25-2025
- CGTX 05-07-2025
- Dividend Yield
- IZM N/A
- CGTX N/A
- EPS Growth
- IZM N/A
- CGTX N/A
- EPS
- IZM N/A
- CGTX N/A
- Revenue
- IZM $177,933,890.00
- CGTX N/A
- Revenue This Year
- IZM N/A
- CGTX N/A
- Revenue Next Year
- IZM N/A
- CGTX N/A
- P/E Ratio
- IZM N/A
- CGTX N/A
- Revenue Growth
- IZM N/A
- CGTX N/A
- 52 Week Low
- IZM $1.18
- CGTX $0.22
- 52 Week High
- IZM $3.19
- CGTX $2.54
- Technical
- Relative Strength Index (RSI)
- IZM 58.92
- CGTX 28.50
- Support Level
- IZM $2.26
- CGTX $0.22
- Resistance Level
- IZM $2.49
- CGTX $0.34
- Average True Range (ATR)
- IZM 0.12
- CGTX 0.03
- MACD
- IZM -0.02
- CGTX -0.01
- Stochastic Oscillator
- IZM 48.00
- CGTX 14.41
About IZM ICZOOM Group Inc.
ICZOOM Group Inc is engaged in the sale of electronic component products to customers in China. These products are used by small and medium-sized enterprises (SMEs) in the consumer electronic industry, Internet of Things (IoT), automotive electronics, and industrial control segment. In addition to the sales of electronic component products, also provides services to customers such as temporary warehousing, logistic and shipping, and customs clearance and charges them additional service commission fees. The company earns maximum revenue from sale of electronic components.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.